- Home
- BGM vs ELTX Comparison
BGM vs ELTX Comparison
Compare BGM & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGM
- ELTX
- Stock Information
- Founded
- BGM 2019
- ELTX 2011
- Country
- BGM China
- ELTX United States
- Employees
- BGM N/A
- ELTX N/A
- Industry
- BGM
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- BGM
- ELTX Health Care
- Exchange
- BGM NYSE
- ELTX Nasdaq
- Market Cap
- BGM 309.0M
- ELTX 54.6M
- IPO Year
- BGM 2021
- ELTX 2021
- Fundamental
- Price
- BGM $9.20
- ELTX $6.07
- Analyst Decision
- BGM
- ELTX Strong Buy
- Analyst Count
- BGM 0
- ELTX 3
- Target Price
- BGM N/A
- ELTX $9.50
- AVG Volume (30 Days)
- BGM 32.9K
- ELTX 25.8K
- Earning Date
- BGM 02-13-2025
- ELTX 11-13-2024
- Dividend Yield
- BGM N/A
- ELTX N/A
- EPS Growth
- BGM N/A
- ELTX N/A
- EPS
- BGM N/A
- ELTX N/A
- Revenue
- BGM N/A
- ELTX N/A
- Revenue This Year
- BGM N/A
- ELTX N/A
- Revenue Next Year
- BGM N/A
- ELTX N/A
- P/E Ratio
- BGM N/A
- ELTX N/A
- Revenue Growth
- BGM N/A
- ELTX N/A
- 52 Week Low
- BGM $1.78
- ELTX $2.96
- 52 Week High
- BGM $14.78
- ELTX $11.45
- Technical
- Relative Strength Index (RSI)
- BGM 48.61
- ELTX 62.00
- Support Level
- BGM $8.80
- ELTX $5.50
- Resistance Level
- BGM $14.78
- ELTX $6.40
- Average True Range (ATR)
- BGM 1.04
- ELTX 0.37
- MACD
- BGM 0.05
- ELTX 0.09
- Stochastic Oscillator
- BGM 14.94
- ELTX 78.43
About BGM QILIAN INTERNATIONAL HLDG GROUP LTD
BGM Group Ltd formerly, Qilian International Holding Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.